

Haematologica  
HAEMATOL/2018/196899  
Version 3

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

Anton Hagenbeek, Hans Mooij, Josée Zijlstra, Pieterella Lugtenburg, Gustaaf Van Imhoff, Marcel Nijland, Sanne Tonino, Martin Hutchings, Marjolein Spiering, Roberto Liu, Harm Van Tinteren, and Marie-José Kersten

Disclosures: This investigator initiated study was financially supported by Takeda Oncology USA and some of the authors have received honoraria for attending advisory boards from Millennium/Takeda.

Contributions: Conception and design: AH and MJK Provision of study materials or patients: all Collection and assembly of data: RL, MS, HvT Data analysis and interpretation: HvT, AH, MJK Manuscript writing: HLM, MJK, AH Final approval of manuscript: all Role of the funding source The funder had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data and had final responsibility to submit for publication.